Compare Recursion Pharmaceuticals Inc (RXRX) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B), while State Street Real Estate Select Sector SPDR ETF trades at $41.61 (market cap $7.61B). The key difference: State Street Real Estate Select Sector SPDR ETF is far larger — about 3.6× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, State Street Real Estate Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and State Street Real Estate Select Sector SPDR ETF for 75 Days on average.
| RXRX | XLRE | |
|---|---|---|
Market Cap | $2.14B | $7.61B |
Volume | 30,789,535 | 7,876,569 |
Sector | Health | Sector/Thematic |
52-Week High | $6.79 | $46.01 |
52-Week Low | $2.84 | $40.01 |
Typical Hold Time | 23 Days | 75 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
XLRE trades at $40.85 with a modest 0.69% daily gain, though technical indicators signal a bearish trend with selling pressure outweighing buying signals 14-5. The ETF's low expense ratio of 0.08% and focus on 30 U.S. large-cap real estate holdings provide cost efficiency, while recent news highlights competition from digital infrastructure ETFs amid rising bond yields.
Outlook remains cautious due to bearish technicals and interest rate sensitivity, though the 3.2% dividend yield offers income appeal. Key risks include Fed policy volatility and sector rotation away from traditional REITs, requiring monitoring of macroeconomic shifts for potential rebound opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
